{"id":291,"date":"2023-07-25T12:43:52","date_gmt":"2023-07-25T12:43:52","guid":{"rendered":"https:\/\/epsilogen.com\/?p=291"},"modified":"2024-03-13T09:58:02","modified_gmt":"2024-03-13T09:58:02","slug":"epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer","status":"publish","type":"post","link":"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/","title":{"rendered":"Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer"},"content":{"rendered":"

Final results of phase I study of MOv18 IgE in ovarian cancer published in Nature Communications
\nMOv18 IgE found to be safe and well tolerated with evidence of anti-tumour activity observed<\/em><\/p>\n

London, 25 July 2023<\/strong>\u00a0\u2013 Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, notes the publication today of the final phase I data from the first ever clinical trial of an IgE antibody therapeutic in\u00a0Nature Communications\u00a0<\/em>(https:\/\/www.nature.com\/articles\/s41467-023-39679-9<\/a>). MOv18 IgE is Epsilogen\u2019s lead IgE antibody drug candidate and binds to anti-folate receptor (FR\u03b1), a well validated target for ovarian cancer. It was administered to 26 patients with high grade serous ovarian carcinoma whose cancer had become platinum-resistant.<\/p>\n

Results from the study, entitled \u201cA Cancer Research UK phase I study of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor-alpha, in patients with advanced solid tumours\u201d (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02546921<\/a>), showed a manageable safety profile with transient urticaria being the most common adverse event. The urticaria always resolved within hours of dosing, either spontaneously or with the administration of systemic steroids and antihistamines.<\/p>\n

Although the trial was not designed to demonstrate efficacy, tumour shrinkage and an associated fall in CA 125 tumour marker level was seen in one patient. Notably, the authors of the paper observed that the anti-tumour activity \u201coccurred at doses very much lower than typically observed for IgG antibodies\u201d, reflecting fundamental differences in Fc-receptor affinity and effector cell biology.<\/p>\n

Professor James Spicer, Professor of Experimental Cancer Medicine at King\u2019s College London, Consultant in Medical Oncology at Guy\u2019s and St Thomas\u2019 NHS Foundation Trust (GSTT) and the study\u2019s lead investigator, said<\/b>: \u201cIgE is a completely new form of antibody therapy which has shown great promise in this phase I trial. Our findings show that the drug was well tolerated in patients and shrunk a cancerous tumour in a patient with ovarian cancer. The results pave the way to development of an entirely new class of anti-cancer drug for people with chemotherapy-resistant cancers. The immunology expertise in King\u2019s College London laboratories allowed us to undertake this trial of a completely new form of antibody therapy<\/i>.\u201d<\/p>\n

Dr Tim Wilson, Chief Executive Officer of Epsilogen, commented:<\/b>\u00a0\u201cThe data published in Nature Communications, are encouraging and add further validation to support our belief that IgE antibodies have the potential to emerge as an entirely new treatment modality for patients with cancer. We have a robust clinical development plan in place to progress MOv18 IgE further into the clinic and the data generated will assist us in the development of our other IgE antibody drug candidates<\/i>\u201d.<\/p>\n

Research Paper Available Here<\/a><\/p>\n

ENDS<\/strong><\/p>\n

About Epsilogen Ltd<\/strong><\/p>\n

Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE\u2019s natural function is to provide immunological defense against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.<\/p>\n

Epsilogen\u2019s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. The company is also developing a proprietary IgEG antibody platform combining elements from both IgE and IgG antibodies into novel and proprietary antibody molecules with enhanced functionality.<\/p>\n

Epsilogen began operations in 2017 as a spin out of King\u2019s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, Alsa Ventures and Schroders Capital amongst others.<\/p>\n

Find out more at\u00a0epsilogen.com<\/a>.<\/p>\n

For more information please contact:<\/strong><\/p>\n

Communications advisor to Epsilogen Ltd:
\nSimon Conway
\nSenior Managing Director
\nFTI Consulting
\nsimon.conway@fticonsulting.com<\/a>
\n+44 (0)20 3727 1000<\/p>\n","protected":false},"excerpt":{"rendered":"

Final results of phase I study of MOv18 IgE in ovarian cancer published in Nature Communications MOv18 IgE found to be safe and well tolerated with evidence of anti-tumour activity observed London, 25 July 2023\u00a0\u2013 Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, notes the publication today of […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"acf":[],"yoast_head":"\nEpsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer - Epsilogen<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer - Epsilogen\" \/>\n<meta property=\"og:description\" content=\"Final results of phase I study of MOv18 IgE in ovarian cancer published in Nature Communications MOv18 IgE found to be safe and well tolerated with evidence of anti-tumour activity observed London, 25 July 2023\u00a0\u2013 Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, notes the publication today of […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Epsilogen\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-25T12:43:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-13T09:58:02+00:00\" \/>\n<meta name=\"author\" content=\"Krishna Thapa\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Krishna Thapa\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/\"},\"author\":{\"name\":\"Krishna Thapa\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/3d0985f07b769ea5d41e88429e6ba369\"},\"headline\":\"Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer\",\"datePublished\":\"2023-07-25T12:43:52+00:00\",\"dateModified\":\"2024-03-13T09:58:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/\"},\"wordCount\":660,\"publisher\":{\"@id\":\"https:\/\/epsilogen.com\/#organization\"},\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/\",\"url\":\"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/\",\"name\":\"Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer - Epsilogen\",\"isPartOf\":{\"@id\":\"https:\/\/epsilogen.com\/#website\"},\"datePublished\":\"2023-07-25T12:43:52+00:00\",\"dateModified\":\"2024-03-13T09:58:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/epsilogen.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/epsilogen.com\/#website\",\"url\":\"https:\/\/epsilogen.com\/\",\"name\":\"Epsilogen\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/epsilogen.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/epsilogen.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/epsilogen.com\/#organization\",\"name\":\"Epsilogen\",\"url\":\"https:\/\/epsilogen.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg\",\"contentUrl\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg\",\"width\":267,\"height\":64,\"caption\":\"Epsilogen\"},\"image\":{\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/3d0985f07b769ea5d41e88429e6ba369\",\"name\":\"Krishna Thapa\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2e66643291fdfef12ec5453a16f98ecf?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2e66643291fdfef12ec5453a16f98ecf?s=96&d=mm&r=g\",\"caption\":\"Krishna Thapa\"},\"url\":\"https:\/\/epsilogen.com\/author\/krishnathapakehorne-co-uk\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer - Epsilogen","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer - Epsilogen","og_description":"Final results of phase I study of MOv18 IgE in ovarian cancer published in Nature Communications MOv18 IgE found to be safe and well tolerated with evidence of anti-tumour activity observed London, 25 July 2023\u00a0\u2013 Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, notes the publication today of […]","og_url":"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/","og_site_name":"Epsilogen","article_published_time":"2023-07-25T12:43:52+00:00","article_modified_time":"2024-03-13T09:58:02+00:00","author":"Krishna Thapa","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Krishna Thapa","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/#article","isPartOf":{"@id":"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/"},"author":{"name":"Krishna Thapa","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/3d0985f07b769ea5d41e88429e6ba369"},"headline":"Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer","datePublished":"2023-07-25T12:43:52+00:00","dateModified":"2024-03-13T09:58:02+00:00","mainEntityOfPage":{"@id":"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/"},"wordCount":660,"publisher":{"@id":"https:\/\/epsilogen.com\/#organization"},"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/","url":"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/","name":"Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer - Epsilogen","isPartOf":{"@id":"https:\/\/epsilogen.com\/#website"},"datePublished":"2023-07-25T12:43:52+00:00","dateModified":"2024-03-13T09:58:02+00:00","breadcrumb":{"@id":"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/epsilogen.com\/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/epsilogen.com\/"},{"@type":"ListItem","position":2,"name":"Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer"}]},{"@type":"WebSite","@id":"https:\/\/epsilogen.com\/#website","url":"https:\/\/epsilogen.com\/","name":"Epsilogen","description":"","publisher":{"@id":"https:\/\/epsilogen.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/epsilogen.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/epsilogen.com\/#organization","name":"Epsilogen","url":"https:\/\/epsilogen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/","url":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg","contentUrl":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg","width":267,"height":64,"caption":"Epsilogen"},"image":{"@id":"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/3d0985f07b769ea5d41e88429e6ba369","name":"Krishna Thapa","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2e66643291fdfef12ec5453a16f98ecf?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2e66643291fdfef12ec5453a16f98ecf?s=96&d=mm&r=g","caption":"Krishna Thapa"},"url":"https:\/\/epsilogen.com\/author\/krishnathapakehorne-co-uk\/"}]}},"_links":{"self":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts\/291"}],"collection":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/comments?post=291"}],"version-history":[{"count":1,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts\/291\/revisions"}],"predecessor-version":[{"id":292,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts\/291\/revisions\/292"}],"wp:attachment":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/media?parent=291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/categories?post=291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/tags?post=291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}